Table of Content

1 INTRODUCTION OF GLOBAL DEMENTIA DRUGS MARKET
1.1 Overview of the MARKET
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL DEMENTIA DRUGS MARKET OUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL DEMENTIA DRUGS MARKET, BY DRUG CLASS
5.1 Overview
5.2 Cholinergic/ cholinesterase inhibitors
5.3 Memantine
5.4 Combination drugs (Memantine and Donepezil)

6 GLOBAL DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.2 Hospital Pharmacies
6.3 Retails
6.4 Online Sales

7 GLOBAL DEMENTIA DRUGS MARKET, BY GEOGRAPHY
7.1 Overview
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 U.K.
7.3.3 France
7.3.4 Rest of Europe
7.4 Asia Pacific
7.4.1 China
7.4.2 Japan
7.4.3 India
7.4.4 Rest of Asia Pacific
7.5 Rest of the World
7.5.1 Latin America
7.5.2 Middle East and Africa

8 GLOBAL DEMENTIA DRUGS MARKET COMPETITIVE LANDSCAPE
8.1 Overview
8.2 Company MARKET Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 Eisai, Inc.
9.1.1 Overview
9.1.2 Financial Performance
9.1.3 Product Outlook
9.1.4 Key Developments

9.2 Janssen Pharmaceuticals, Inc.
9.2.1 Overview
9.2.2 Financial Performance
9.2.3 Product Outlook
9.2.4 Key Developments

9.3 Biogen Pharmaceuticals
9.3.1 Overview
9.3.2 Financial Performance
9.3.3 Product Outlook
9.3.4 Key Developments

9.4 Forest Laboratories, Inc.
9.4.1 Overview
9.4.2 Financial Performance
9.4.3 Product Outlook
9.4.4 Key Developments

9.5 Eli Lilly and Company
9.5.1 Overview
9.5.2 Financial Performance
9.5.3 Product Outlook
9.5.4 Key Developments

9.6 Novartis AG
9.6.1 Overview
9.6.2 Financial Performance
9.6.3 Product Outlook
9.6.4 Key Developments

9.7 Sanofi S.A.
9.7.1 Overview
9.7.2 Financial Performance
9.7.3 Product Outlook
9.7.4 Key Developments

9.8 AstraZeneca GmbH
9.8.1 Overview
9.8.2 Financial Performance
9.8.3 Product Outlook
9.8.4 Key Developments

9.9 F.Hoffmann-La Roche.
9.9.1 Overview
9.9.2 Financial Performance
9.9.3 Product Outlook
9.9.4 Key Developments

9.10 Merck & Co., Inc.
9.10.1 Overview
9.10.2 Financial Performance
9.10.3 Product Outlook
9.10.4 Key Developments